We are live on ! Find out more
HS

HighVista Strategies Portfolio holdings

AUM $362M
1-Year Est. Return 230.96%
This Fund
S&P 500
This Quarter Est. Return
+14.9%
1 Year Est. Return
+230.96%
3 Year Est. Return
+518.4%
5 Year Est. Return
+644.94%
10 Year Est. Return
+2,223.31%
AUM
$272M
AUM Growth
+$12.6M
Cap. Flow
-$13.6M
Cap. Flow %
-4.98%
Top 10 Hldgs %
27.33%
Holding
177
New
29
Increased
50
Reduced
55
Closed
31

Top Buys

Rank Stock Value
1
VRDN icon
Viridian Therapeutics
VRDN
+$4.13M
2
MLYS icon
Mineralys Therapeutics
MLYS
+$2.18M
3
CLDX icon
Celldex Therapeutics
CLDX
+$2.07M
4
CLF icon
Cleveland-Cliffs
CLF
+$1.9M
5
FERG icon
Ferguson
FERG
+$1.82M

Top Sells

Rank Stock Value
1
ACI icon
Albertsons Companies
ACI
+$4.15M
2
SWTX
SpringWorks Therapeutics
SWTX
+$3.03M
3
GEV icon
GE Vernova
GEV
+$2.41M
4
GOOG icon
Alphabet (Google) Class C
GOOG
+$2.1M
5
BHC icon
Bausch Health
BHC
+$2.03M

Sector Composition

Rank Sector Weight
1 Healthcare 37.62%
2 Technology 22.09%
3 Industrials 8.52%
4 Financials 6.08%
5 Consumer Discretionary 5.13%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
INTU icon
26
Intuit
INTU
$91.5B
$2.57M 0.94%
3,263
-600
-16% -$406K
RVMD icon
27
Revolution Medicines
RVMD
$44.4B
$2.5M 0.92%
68,048
-5,704
-8% -$219K
NVDA icon
28
NVIDIA
NVDA
$5.27T
$2.48M 0.91%
15,700
+1,100
+8% +$138K
PWR icon
29
Quanta Services
PWR
$99.4B
$2.42M 0.89%
6,400
-1,700
-21% -$546K
ACLX
30
DELISTED
Arcellx
ACLX
$2.35M 0.86%
35,714
-11,782
-25% -$733K
AGIO icon
31
Agios Pharmaceuticals
AGIO
$1.95B
$2.33M 0.86%
70,127
+26,022
+59% +$789K
META icon
32
Meta Platforms (Facebook)
META
$1.52T
$2.29M 0.84%
3,100
-100
-3% -$61.8K
V icon
33
Visa
V
$675B
$2.28M 0.84%
6,427
+300
+5% +$105K
CYTK icon
34
Cytokinetics
CYTK
$10.5B
$2.27M 0.83%
68,652
+23,903
+53% +$831K
MA icon
35
Mastercard
MA
$493B
$2.25M 0.83%
4,000
+300
+8% +$166K
MMM icon
36
3M
MMM
$93.9B
$2.19M 0.81%
14,400
+900
+7% +$129K
AMD icon
37
Advanced Micro Devices
AMD
$767B
$2.19M 0.8%
+15,400
New +$1.68M
CLDX icon
38
Celldex Therapeutics
CLDX
$3.37B
$2.17M 0.8%
+106,553
New +$2.07M
FERG icon
39
Ferguson
FERG
$51.1B
$2.15M 0.79%
+9,878
New +$1.82M
GEV icon
40
GE Vernova
GEV
$264B
$2.12M 0.78%
4,000
-5,800
-59% -$2.41M
BKNG icon
41
Booking.com
BKNG
$160B
$2.07M 0.76%
8,925
– –
COGT icon
42
Cogent Biosciences
COGT
$7.09B
$2.03M 0.75%
283,186
+3,513
+1% +$19.5K
MLYS icon
43
Mineralys Therapeutics
MLYS
$2.41B
$2.03M 0.75%
+150,138
New +$2.18M
SNPS icon
44
Synopsys
SNPS
$78.8B
$2M 0.73%
3,900
+800
+26% +$373K
LYFT icon
45
Lyft
LYFT
$6.56B
$1.98M 0.73%
+125,800
New +$1.76M
APGE icon
46
Apogee Therapeutics
APGE
$10.2B
$1.96M 0.72%
45,052
+1,862
+4% +$70.8K
CLF icon
47
Cleveland-Cliffs
CLF
$7.13B
$1.94M 0.71%
+255,600
New +$1.9M
APH icon
48
Amphenol
APH
$207B
$1.88M 0.69%
19,000
-3,900
-17% -$319K
MTZ icon
49
MasTec
MTZ
$21.5B
$1.87M 0.69%
11,000
-5,300
-33% -$763K
QXO
50
QXO Inc
QXO
$16.6B
$1.82M 0.67%
84,500
-19,000
-18% -$312K
1
2
3 4 5

Similar funds

SIAG
Safeguard Investment Advisory Group Corona, California $362M AUM 20.96% 1-Year Est. Return
WI
WBI Investments Red Bank, New Jersey $362M AUM 23.75% 1-Year Est. Return
MS
Millington Securities Red Bank, New Jersey $362M AUM
WTFG
Wood Tarver Financial Group Boise, Idaho $362M AUM 14.75% 1-Year Est. Return
VIA
Virtus Investment Advisers Hartford, Connecticut $363M AUM 34.89% 1-Year Est. Return
A6
Anchor @ 65 Singapore $362M AUM 20.02% 1-Year Est. Return
PI
Pennant Investors Summit, New Jersey $361M AUM 134.26% 1-Year Est. Return
ACM
Anfield Capital Management Irvine, California $363M AUM 24.08% 1-Year Est. Return

HighVista Strategies's Q2 2025 Portfolio in Review

As of Q2 2025, HighVista Strategies held 177 positions worth $272M, up 4.9% from $260M the previous quarter. Its ten largest holdings account for 27% of the portfolio.

HighVista Strategies withdrew a net $13.6M in Q2 2025, closing 31 positions and reducing 55 holdings. Its most notable exit was Albertsons Companies, an estimated $4.15M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 38% of assets, down from 39% a quarter earlier, followed by Technology and Industrials.

Against the trend, HighVista Strategies opened a new position in Mineralys Therapeutics worth $2.03M.

  • HighVista Strategies's largest Q2 2025 buy was Mineralys Therapeutics: 150,138 shares worth $2.03M.
  • HighVista Strategies added most to Viridian Therapeutics in Q2 2025, an estimated $4.13M increase.
  • HighVista Strategies's biggest Q2 2025 reduction was GE Vernova, cutting an estimated $2.41M.
  • HighVista Strategies fully exited Albertsons Companies in Q2 2025, selling an estimated $4.15M.
  • HighVista Strategies's ten largest holdings make up 27% of its $272M portfolio in Q2 2025.
  • HighVista Strategies opened 29 new positions and closed 31 in Q2 2025.
  • HighVista Strategies's portfolio value rose 4.9% quarter-over-quarter to $272M.

Based on HighVista Strategies's 13F filing for Q2 2025, filed 14 Aug 2025.